Fexofenadine hydrochloride in the treatment of allergic disease: a review by Axelrod, David & Bielory, Leonard
© 2008 Dove Medical Press Limited.   All rights reserved
Journal of Asthma and Allergy 2008:1 19–29 19
REVIEW
Fexofenadine hydrochloride in the treatment 
of allergic disease: a review
David Axelrod1
Leonard Bielory2
Division of Allergy, Immunology 
and Rheumatology, UMDNJ-New 
Jersey Medical School, 
1Department of Medicine, 
2Departments of Medicine, 
Pediatrics, Ophthalmology 
and Visual Sciences, 
Newark, New Jersey, USA
Correspondence: Leonard Bielory
UMDNJ – New Jersey Medical School, 90 
Bergen Street, DOC Suite 4700, Newark, 
New Jersey 07103, USA
Tel +1 973 972 2768
Fax +1 973 972 2769
Email bielory@umdnj.edu
Abstract: Fexofenadine is a selective, non-sedating H1 receptor antagonist, marketed in the 
United States since 2000. The FDA approved an oral suspension in 2006, for the treatment of 
seasonal allergic rhinitis and chronic idiopathic urticaria in children. The tablet, capsule, and 
oral suspension are bioequivalent. Although fexofenadine does not use P450 CYP 3A4 it does 
interact with a number of drugs at P-glycoprotein and organic anion transporter polypeptides. 
The risk of toxicity from other drugs may increase with the administration of fexofenadine. 
Orange and grapefruit juices reduce the bioavailability of fexofenadine. Fexofenadine has been 
shown to have an impact on inﬂ  ammatory mediators, other than histamine, such as decreasing 
the production of LTC4, LTD4, LTE4, PGE2, and PGF2α; inhibiting cyclo-oxygenase 2, throm-
boxane; limiting iNOS generation of NO; decreasing cytokine levels (ICAM-1, ELAM-1, 
VCAM-1, RANTES, I-TAC, MDC, TARC, MMP-2, MMP-9, tryptase); and diminishing 
eosinophil adherence, chemotaxis, and opsonization of particles. These effects may provide 
beneﬁ  t to some of the inﬂ  ammatory responses of an acute allergic reaction and provide a basis 
for future development of H1 antagonists with stronger anti-inﬂ  ammatory effects. These studies 
also support the contention that fexofenadine is effective for the treatment of allergic rhinits 
and chronic idiopathic urticaria.
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Introduction
The allergic response in people with atopic disorders involves exposure of the immune 
system to the antigen (Leung 1998), antigen presentation (Fokkens et al 1991), mediator 
release with ampliﬁ  cation signals (Grewal and Flavell 1996; Vercelli et al 1989), and 
production of antigen speciﬁ  c IgE, which binds to mast cells. (Ishizaka and Ishizaka 
1977). Upon re-exposure to the allergen, bridging of the mast cell bound allergen 
speciﬁ  c IgE results in the release of preformed and newly synthesized bioactive and 
pro-inﬂ  ammatory mediators (Hirano 1989), which results in the symptoms of allergic 
rhinitis and chronic idiopathic urticaria, and contributes to the symptoms of atopic 
dermatitis and allergic asthma.
Antihistamines form the cornerstone of treatment for allergic disorders. Fexofena-
dine has been marketed in the US as a selective H1 antagonist since 2000. However, 
the drug appears to exhibit some anti-inﬂ  ammatory activity. The US Food and Drug 
Administration (FDA) approved an oral suspension of fexofenadine on October 16, 
2006. The approval is for twice-daily dosing, for the treatment of symptoms associated 
with seasonal allergic rhinitis, in patients 2 to 11 years of age, and for the treatment of 
symptoms of chronic idiopathic urticaria, in patients 6 months to 11 years of age.
The studies cited in this text provide information based upon other oral formula-
tions of fexofenadine. Information on fexofenadine oral suspension remains sparse. 
Information based upon efﬁ  cacy studies ﬁ  nancially supported only by the manufacturer 
is not included, unless stated in the text.Journal of Asthma and Allergy 2008:1 20
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Bioequivalence of oral suspension 
and solid formulations 
of fexofenadine
Morrison and Sahasranaman (2007) administered fexofena-
dine 30 mg by tablet or by oral suspension to 53 normal adult 
subjects. Their subjects reached maximum blood fexofena-
dine concentrations at 1 hour for the oral suspension and 
1.5 hour for the tablet. They found equivalent areas under 
the curves for the oral suspension and the tablet formulation, 
suggesting bioequivalence of fexofenadine oral suspension 
and fexofenadine capsules. In a study focusing on the oral 
formulations, Grubbe et al (2007) evaluated the pharma-
cokinetics of fexofenadine oral suspension in 50 children, 
aged 2 to 5 years, which demonstrated the mean maximum 
plasma concentration of 224 ng/mL, and the mean area 
under the plasma concentration curve of 898 ng-h/mL. In 
capsule formulations in a double-blind, two-way crossover 
study in children with allergic rhinitis (with a mean age of 
9.8 years, a mean height of 134 cm and a mean weight of 
32.1 kg), Simons et al (1996) administered 30 or 60 mg 
of fexofenadine as a capsule and demonstrated the mean 
maximum plasma concentrations after the 30 mg dose of 
78 ng/mL, and the mean maximum concentrations after the 
60 mg dose of 286 ng/mL. They found no dose-dependent 
kinetics in the doses studied and no difference in the clear-
ance rates or the mean terminal elimination half-life values 
after both doses. In another capsule and tablet formulation 
study designed as open-label, randomized crossover studies 
in healthy male non-smokers 18 to 43 years of age, within 
10% of ideal body weight, Stoltz et al (1997) found that the 
relative bioavailability of fexofenadine capsules is 89% to 
93% compared to the tablet formulation. Food decreased the 
area under the curves by 17% for the capsule and by 25% 
for the tablet compared to administration of the fexofenadine 
under a fasting state. Food did not change the proportionality 
of the fexofenadine pharmacokinetics.
These studies suggest that fexofenadine is bioequivalent 
in its three oral formulations.
Pharmacokinetics
In an industry-based1 study, Robbins et al (1998) studied 
the pharmacokinetics of fexofenadine in 24 healthy male 
adult volunteers. The drug was undetectable at 48 hours 
after a single dose, and percent drug recovered in the urine 
ranged from 7.6% to 11.8%. In another industry-based 
study, Russell et al (1998) found similar pharmacokinetics, 
in healthy male adults, for both the single dose and twice-
daily dose of fexofenadine, administered as an oral solu-
tion, with 80% of the administered drug passing through 
the intestinal tract (Russell et al 1998). These two studies 
suggest that the majority of the drug is excreted through 
the intestinal tract, with a small component via the kidneys, 
mostly unchanged.
Although high doses of fexofenadine do not appear to 
provide much toxicity, interaction with other drugs that use 
the P450 CYP3A4 degradation pathway, P-glycoprotein and 
the organic anion transporter peptides, prominent transporter 
proteins, may increase the risks of adverse events (Shukla 
et al 2008). Concomitant exposure to prescription and non-
prescription drugs, as well as food, may signiﬁ  cantly alter the 
blood and tissue levels of medications, as well as alter the risks 
to those medications. Factors that may affect the drug–drug 
and drug–food interactions include biodegradative pathways 
and transport mechanisms, particularly via the multi-drug 
transporters P-glycoprotein and organic anion transporter 
(Table 1) (Adenot et al 2004; Akiyama et al 1988; Baltes et al 
2007; Charuk et al 1994; Chiou et al 2000; Choi et al 1998; 
Crowe et al 2006a, b; DiDiodato and Sharom 1997; Doran 
et al 2005; Ejsing et al 2007; Elsinga et al 2004; Faassen et al 
2003; Feng et al 2008; Fromm 2000; Garrigues et al 2002; 
Gouaze et al 2005; Hanko et al 2003; Hayeshi et al 2006; 
Ibrahim et al 2000; Ito et al 1997; Jette et al 1995; Johnson 
2002; Ketabi-Kiyanvash et al 2003; Kim and Kim 2002; King 
et al 2001; Lee and Lee 2002; Leung and Bendayan 1999; 
Ling 1992; Litman et al 2003; Loo et al 2003; Makowski 
and Pikula 1997; Mollgard et al 2001; Neuhoff et al 2000; 
Orlowski and Garrigos 1999; Pascaud et al 1998; Rebbeor 
and Senior 1998; Safa and Safa 2004; Savolainen et al 2002; 
Schinkel et al 1996; Sharom 1997; Shirasaka et al 2006; 
Shukla et al 2008; Smit et al 1998; Storch et al 2007; Terao 
et al 1996; Wang et al 2006; Weiss et al 2003).
Although sterioisomers are commonly found to have some 
preferential biological and pharmacological effects (Bielory 
et al), Miura et al (2007) did not ﬁ  nd any difference in the 
pharmacokinetics of fexofenadine enantiomers in healthy sub-
jects. They found that neither enantiomer underwent metabo-
lism by CYP3A4. In addition, alfentanil, a selective inhibitor of 
the P450 CYP3A4 degradative pathway, did not signiﬁ  cantly 
compete with fexofenadine (Kharasch et al 2005). Therefore, 
it appears that fexofenadine does not signiﬁ  cantly interact with 
the P450 CYP3A degradative pathway. However, in a study 
1Hoechst Marion Roussel ﬁ  rst marketed fexofenadine. In 1999, Hoechst AG 
(parent company to Hoechst Marion Roussel) merged with Rhône-Poulenc 
to form Aventis, which was absorbed into Sanoﬁ  -Aventis in 2004.Journal of Asthma and Allergy 2008:1 21
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using MDR1a/1b knockout mice, Tahara et al (2005) showed 
that P-glycoprotein does have a role in moving fexofenadine 
from the brain to the plasma, and from the plasma to the liver, 
but had no effect on fexofenadine biliary excretion.
Cvetkovic et al (1999) found that the human organic anion 
transporting polypeptide mediates 14C-labeled fexofenadine 
cellular uptake. The bile acid transporter, human sodium 
taurocholate co-transporting polypeptide, did not exhibit 
such activity. The authors identiﬁ  ed P-glycoprotein as a 
fexofenadine efﬂ  ux transporter, using the LLC-PK1 cell, 
a polarized epithelial cell line that lacks P-glycoprotein, 
and a derivative cell line (L-MDR1), which overexpresses 
P-glycoprotein. Oral and intravenous administration of 
14C-labeled fexofenadine to mice lacking MDR1-encoded 
P-glycoprotein resulted in 5- and 9-fold increases in the 
drug’s plasma and brain levels, respectively, compared 
with wild-type mice. A number of drug inhibitors of 
P-glycoprotein effectively inhibited organic anion trans-
porting polypeptide. Because organic anion transporting 
polypeptide transporters and P-glycoprotein co-localize 
in organs of importance to drug disposition, such as the 
liver, their activity may provide an explanation for the 
mechanism(s) responsible for fexofenadine disposition, and 
suggests potentially similar roles in the disposition of other 
xenobiotics (Cvetkovic et al 1999).
Inhibitors of P-glycoprotein (ketoconazole, itraconazole, 
verapamil, and erythromycin) inhibited the intestinal absorp-
tion of fexofenadine. However, inhibitors of multidrug 
resistant associated protein (indomethacin, probenecid) 
and organic anion transporting polypeptide (rifamycin) had 
no effect upon fexofenadine transport. Rifampin increases 
fexofenadine clearance, presumably by the induction of 
P-glycoprotein (Hamman et al 2001). Fexofenadine does 
not appear to affect the pharmacokinetics of omeprazole, a 
substrate of P-glycoprotein, suggesting that these two drugs 
have different transport mechanisms, or fexofenadine does 
not saturate P-glycoprotein.
Drescher et al (2002) described a number of distinct 
P-glycoprotein mutations that may affect the transport of 
fexofenadine. The MDR1 G2577T/C3435T haplotype of 
P-glycoprotein, in the presence of itraconazole, altered the 
disposition of fexofenadine, with no change in the elimination 
half-life and the renal clearance of fexofenadine. Itracon-
azole resulted in a 3-fold increase in the peak concentration 
of fexofenadine and the area under the curve. It increased 
the mean area under the plasma concentration-time curve 
of fexofenadine. This suggests that the interaction between 
itraconazole and fexofenadine may occur at the gut wall 
before reaching the portal vein circulation. The C3435T 
mutation does not affect the disposition of fexofenadine. 
Table 1 Site and effect of drug interactions with fexofenadine
Drug Interaction Effect of interaction on fexofenadine 
peak concentration
Ketoconazole Inhibit P-glycoprotein Decrease intestinal absorption and increased 
fexofenadine peak concentration
Itraconazole Inhibit P-glycoprotein Decrease intestinal absorption and increased 
fexofenadine peak concentration
Verapamil Inhibit P-glycoprotein Decrease intestinal absorption and increased 
fexofenadine peak concentration
Erythromycin Inhibit P-glycoprotein Decrease intestinal absorption and increased 
fexofenadine peak concentration
Ritonavir Inhibit P-glycoprotein Decrease intestinal absorption and increased 
fexofenadine peak concentration
Lopinavir/ritonavir Inhibit P-glycoprotein Decrease intestinal absorption and increased 
fexofenadine peak concentration
St John’s Wort Inhibit P-glycoprotein Decrease intestinal absorption and increased 
fexofenadine peak concentration
Omeprazole Interacts at P-glycoprotein None
Indomethacin Inhibit multidrug resistant-associated protein None
Probenecid Inhibit multidrug resistant-associated protein Decreased renal clearance and no change in 
peak concentration
Rifamycin Inhibit organic anion-transporting 
polypeptide
None
Rifampin Induction of P-glycoprotein Increased fexofenadine clearanceJournal of Asthma and Allergy 2008:1 22
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However, subjects with the 2677AA/3435CC haplotype had 
lower plasma fexofenadine concentrations than those with 
the G2677T/A and C3435T haplotypes (Yi et al 2004). These 
ﬁ  ndings suggest that P-glycoprotein is responsible for the 
intestinal absorption of fexofenadine.
Van Heeswijk et al (2006) studied the time-dependent 
interaction between lopinavir/ritonavir and fexofenadine. 
Ritonavir and lopinavir/ritonavir increased the area under the 
plasma concentration-time curve for fexofenadine. They did 
not observe a change in the fexofenadine elimination half-
life. They postulated that the increased area under the curve 
related to increased bioavailability due to P-glycoprotein 
inhibition. This effect of lopinavir/ritonavir would inhibit 
the intestinal elimination of fexofenadine. St John’s Wort, 
in a single dose of 900 mg, inhibits the intestinal transport of 
fexofenadine, increasing the maximum plasma concentration 
of fexofenadine by 45%. St John’s wort decreases the oral 
clearance of fexofenadine by 20%, without changing the 
half-life and renal clearance (Milne et al 2000; Petri et al 
2004; Shon et al 2005; Takahata et al 2004; Tannergren et al 
2003; Uno et al 2006; Wang et al 2002). These data suggest 
that fexofenadine may affect the blood levels of other drugs 
through its interaction with P-glycoprotein.
Probenecid has been shown to inhibit the interaction of 
fexofenadine with the organic anion transporter 3 (OAT3) 
in the kidney (Tahara et al 2006). However, as the renal 
excretion of fexofenadine is small (10%), the effect upon 
systemic fexofenadine levels is limited (Robbins et al 1998). 
There may also be preferential binding of fexofenadine 
by OAT subtypes. Organic anion transporter Protein 1B3 
preferentially accepts fexofenadine over organic anion trans-
porter proteins 1B1 and 2B1 in human embryonic kidney 
cells, suggesting that organic anion transporter Protein 1B3 
is a transporter involved in hepatic uptake of fexofenadine 
(Shimizu et al 2005).
Although fexofenadine does not undergo signiﬁ  cant 
metabolism by the P450 CYP 3A4, it does interact with a 
numbers of drugs at P-glycoprotein and the organic anion 
transporter polypeptides. These interactions may increase 
the blood levels of a number of drugs, and increase the risk 
of adverse effects with concomitant administration of those 
drugs.
Fruit juices and their effect 
upon fexofenadine absorption
Administration of fexofenadine with grapefruit juice reduces 
the bioavailability of fexofenadine (Banﬁ  eld et al 2002). This 
reduction in bioavailability, which also occurs with apple 
juice, appears to result from preferential inhibition of organic 
anion transporter polypeptide mediated transport (Dresser 
et al 2002, 2005; Kamath et al 2005). These data have led 
to the recommendation that patients should not ingest apple 
or grapefruit juice while taking fexofenadine.
Mechanism of action (Table 2)
At 1 to 2 hours following the ingestion of fexofenadine, both 
the 30 mg and 60 mg doses suppressed the epicutaneous 
wheal response to histamine through 24 hours post dosing 
and suppressed the epicutaneous ﬂ  are response to histamine 
through 8 hours post dosing (Simons et al 2003). In another 
study, fexofenadine inhibited the histamine-induced wheal 
and ﬂ  are with a maximum effect reached between 1 and 
2 hours and lasting through the 12-hour dosing schedule 
Table 2 Mechanisms of action of fexofenadine on components of 
the immune system
Component of immune 
system
 Effect  of  fexofenadine
H1 receptor Competitive inhibition
LTC4, LTD4, and LTE4 Inhibit production
PGE2 and PGF2α Inhibit production
Cyclo-oxygenase 2 Competitive inhibition
Thromboxane Inhibit production
iNOS mRNA Inhibit production
ELAM-1 Inhibit production
VCAM-1 Inhibit production
Tryptase Inhibit production
Nasal epithelial cells Attenuate electrical resistance 
to eosinophils and opsonized 
latex beads
Decreased release of IL-6 and 
TNFα
Mucosal ﬁ  broblasts Decreased release of MMP-2 
and MMP-9
Eosinophils Decreased release of RANTES
Decreased release of IL-8
Decreased release of GM-CSF
Decreased release of sICAM-1
Decreased IFNγ- and TNFα-
induced release of ICAM-1
Decreased trichinella-induced 
eosinophilia
Keratinocyte Decreased expression RANTES
Decreased expression of I-TAC
Decreased expression of MDC 
and TARC
Peripheral blood leukocyte  Decreased production of IL-4Journal of Asthma and Allergy 2008:1 23
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for 60 mg, while the fexofenadine 120 mg dose inhibited 
the histamine-induced wheal and ﬂ  are for 23 hours. The 
authors did not note tolerance to the anti-histamine effect 
over a period of 28 days (Russell et al 1998). Allocco et al 
(2002), with grants from the NIH and industry, studied 
the effect of fexofenadine upon the early response to nasal 
allergen challenge and demonstrated that fexofenadine 
reduced symptoms and vascular permeability. However, 
it did not reduce the release of histamine or tryptase. Their 
data suggest that while fexofenadine antagonizes mediators 
of the acute allergic response, it does not prevent mast cell 
degranulation.
Older anti-histamines have anti-cholinergic properties 
that may induce increased intraocular pressure, leading to 
glaucoma and prostatism associated with urinary retention. 
However, in a cholinergic linked capsaicin-induced cough 
model, pretreatment with fexofenadine had no adverse effect 
(Dicpinigaitis et al 2003).
In an industry-sponsored study, Juergens et al (2006a) 
evaluated the effect of fexofenadine on arachidonic acid 
metabolism in cultured human monocytes. Lipopolysaccharide 
stimulated human monocytes from healthy volunteers 
co-cultured with and without fexofenadine, followed by 
stimulation with zymosan, led to inhibition of LTC4, LTD4, 
and LTE4 production. Fexofenadine also inhibited lipo-
polysaccharide-stimulated production of PGE2 and PGF2α, 
which the authors suggest may explain the beneﬁ  cial effects 
of fexofenadine upon nasal congestion. In addition, fexof-
enadine selectively inhibited cyclo-oxygenase 2, which may 
also contribute to its apparent anti-inﬂ  ammatory properties 
(Juergens et al 2006b). Sakairi et al (2005), in an industry-
based study, demonstrated that fexofenadine inhibited the 
increase in nasal airway resistance in a guinea pig antigen-
induced model of rhinitis. They found a similar result with 
ramatroban, a thromboxane inhibitor. They did not reduce 
nasal airway resistance with a selective leukotriene antago-
nist. The authors suggest that fexofenadine may inhibit the 
release of chemical mediators, including thromboxane, to 
reduce antigen-induced nasal airway resistance, in part by 
its inhibitory effect on cyclo-oxygenase 2.
Asano et al (2007), in an industry-sponsored study, evalu-
ated the effect of nitric oxide production by fexofenadine 
from nasal ﬁ  broblasts, which demonstrated inhibition of 
iNOS mRNA, with the suppression of TNFα-induced NO 
production from nasal ﬁ  broblasts. Mice treated for 2 and 
3 weeks with fexofenadine had diminished LPS-induced 
NO production with inhibition of iNOS mRNA expression 
in lung tissues, suggesting a role for fexofenadine in asthma. 
However, Brannan et al (2001) and Fardon et al (2005) did 
not show a direct beneﬁ  t of fexofenadine in patients with 
asthma.
Fexofenadine treatment appeared to decrease endothelial 
leukocyte adhesion molecule-1 (ELAM-1), vascular cell 
adhesion molecule-1 (VCAM-1), and tryptase in subjects 
with chronic idiopathic urticaria, suggesting that fexofena-
dine may express other anti-inﬂ  ammatory properties by the 
modulation of these cytokines (Cassano et al 2002).
Abdelaziz et al (1998) studied the effects of fexofena-
dine on eosinophil-induced changes in electrical resistance 
and adherence to human nasal endothelial cells, as well as 
the effects of fexofenadine on eosinophil adherence and 
chemotaxis, in the presence and absence of opsonized latex 
beads. Fexofenadine signiﬁ  cantly attenuated the decrease 
in electrical resistance of the human nasal epithelial cells 
with exposure to both eosinophils and opsonized latex 
beads. Human nasal epithelial cells, on exposure to eosino-
phils with opsonized latex beads, released RANTES, IL-8, 
GM-CSF, and sICAM-1. Fexofenadine diminished the 
release of these chemokines with human nasal epithelial 
cell exposure to eosinophils and opsonized latex beads. In 
the presence of IFNγ and TNFα, fexofenadine decreased 
the expression of ICAM-1, increased the percentage of 
apoptotic cells, but did not change the expression of LFA-1. 
Fexofenadine did not change the expression of keratinocyte 
expression of IL-8 and Mig, but fexofenadine did down-
modulate keratinocyte RANTES, I-TAC, MDC, and TARC, 
suggesting that fexofenadine had a selective effect on TH2 
cytokines, a mechanism by which fexofenadine provided 
an anti-inﬂ  ammatory effect. Fexofenadine did not affect 
peripheral blood leukocyte proliferation induced by Cry j 
1 stimulation. However, fexofenadine signiﬁ  cantly inhibited 
the ability of peripheral blood leukocytes to produce IL-4, 
but not IFN-γ with Cry j 1 stimulation (Asano et al 2004b). 
Fexofenadine pretreatment reduced the intranasal levels of 
IL-6 and TNFα in subjects given an intranasal challenge of 
Parietaria ofﬁ  cinalis (Ciprandi et al 2004).
Watanabe et al (2004) studied the effect of fexofena-
dine upon eosinophilia and systemic anaphylaxis in mice 
infected with Trichinella spiralis. Fexofenadine provided 
a dose-dependent suppression of eosinophilia in C57BL/6 
mice but not in mast cell-deﬁ  cient W/Wv mice. Fexofena-
dine suppressed rectal temperature, a marker for systemic 
anaphylaxis, in C57BL/6 mice. In an IgE-anti-IgE model 
of anaphylaxis in CBF1 mice, fexofenadine suppressed this 
same marker of anaphylaxis, without an effect on peripheral 
IL-5 or eotaxin levels. Fexofenadine diminished mRNA Journal of Asthma and Allergy 2008:1 24
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expression of RANTES, as well as limited the elaboration 
of eotaxin from nasal polyp ﬁ  broblasts, in response to LPS 
(Asano et al 2004a).
Fexofenadine inhibited the production of matrix metal-
loproteinases (MMP) MMP-2 and MMP-9 from nasal polyp 
and mucosal ﬁ  broblasts in response to TNF-α, and inhibited 
MMP mRNA expression and NF-κB, but not tissue inhibitor 
of metalloproteinase (TIMP-1 and TIMP-2) (Asano et al 
2004c). Fexofenadine improved performance on the Digit 
Symbol Substitution Test, but it did not have a blocking effect 
upon the dopamine transporter (Theunissen et al 2006a, b)
Fexofenadine is primarily prescribed for its H1 antagonist 
activity. However, it appears to have effects upon other mast 
cell mediators, as well as mediators produced by other cell 
types. Fexofenadine, in addition to antagonizing H1 receptors, 
decreases the production of LTC4, LTD4, and LTE4, PGE2, 
and PGF2α, inhibits cyclo-oxygenase 2, inhibits the genera-
tion of thromboxane (perhaps through cyclo-oxygenase 2), 
and limits the iNOS generation of NO, as well as the gen-
eration of ICAM-1, ELAM-1, VCAM-1, RANTES, I-TAC, 
MDC, TARC, MMP-2, MMP-9, and tryptase. Fexofenadine 
appears to decrease eosinophil adherence, chemotaxis, and 
opsonization of particles. These effects may decrease the 
inﬂ  ammatory responses initiated by an acute allergic reaction 
and provide a basis for future development of H1 antagonists 
with stronger anti-inﬂ  ammatory effects.
Efﬁ  cacy and safety
Fexofenadine reduced airway sensitivity to mannitol com-
pared to placebo. However, fexofenadine did not alter the 
ﬁ  nal percent reduction in FEV1 (Brannan et al 2001). In trans-
fer experiments, fexofenadine prevented the development of 
airway hyper-responsiveness as well as primary sensitization 
and challenge, with a decrease in bronchoalveolar lavage and 
tissue eosinophilia, lymphocyte numbers, and TH2 cytokine 
production (Gelfand et al 2002). However, fexofenadine did 
not have an additive effect to inhaled corticosteroid therapy 
or on inﬂ  ammatory markers in subjects with atopic asthma 
(Fardon et al 2005).
In children aged 2 to 5 years with allergic rhinitis, 
fexofenadine had a frequency of adverse effects no different 
from placebo. The most frequently involved adverse events 
were upper respiratory tract infection, fever, infection, and 
vomiting. Of the adverse events, 8.2% were attributable to the 
placebo, and 9.5% to fexofenadine. There were no clinically 
relevant differences for laboratory measures, vital signs, and 
physical examinations (Milgrom et al 2007). Grubbe et al 
(2007) evaluated effects of fexofenadine oral suspension 
in 50 children, aged 2 to 5 years. Seven of their subjects 
experienced 10 adverse events, which resolved without 
sequelae. One subject suffered pyrexia. Ngamphaiboon et al 
(2005) studied the efﬁ  cacy and safety of fexofenadine 30 mg 
in pediatric patients with allergic rhinitis. No adverse event 
resulted in dropout. Headache was the most common reported 
adverse event. In their 88 subjects, they did not appreciate 
“meaningful change in any electrocardiogram”.
In a double blind, two-way crossover study, Simons 
et al (1996) administered 30 or 60 mg of fexofenadine as 
a capsule to 14 children with allergic rhinitis (mean age of 
9.8 years, with a mean height of 134 cm and a mean weight of 
32.1 kg). Somnolence occurred in one child 10 hours after the 
ingestion of a 30 mg dose. They found no electrocardiogram 
abnormalities at peak plasma concentrations.
Miyabe et al (2003) studied the effect of fexofenadine 
upon cedar pollinosis. They found that fexofenadine admin-
istered before or after the onset of cedar pollinosis prevented 
or controlled nasal obstruction, sneeze, and rhinorrhea.
In a multi-center placebo controlled safety and efﬁ  cacy 
study of 861 subjects with moderate to severe autumn 
allergic rhinitis, fexofenadine at doses of 120 mg and 180 mg 
fexofenadine, given once daily, signiﬁ  cantly reduced total 
symptom score (for nasal congestion), through the 24-hour 
trough. There were no differences between the two doses of 
fexofenadine and placebo groups in adverse events, as both 
subjects and controls reported headache as the most common 
adverse event (Casale et al 1999).
Fexofenadine had no effect on the quality of life and 
work productivity in adult subjects with seasonal allergic 
rhinitis during the peak season for cedar pollinosis (Okubo 
et al 2005).
Bronsky et al (1998) studied 550 subjects who had 
previously responded to other anti-histamines for seasonal 
allergic rhinitis, for 17 days. Subjects sustained signiﬁ  cant 
improvements in total symptom score 1 to 3 hours after the 
ﬁ  rst dose at doses of 40 mg, 60 mg, and 120 mg, all twice 
daily. Adverse events occurred in about 13% of both the 
fexofenadine and placebo groups. These authors did not 
ﬁ  nd increases in the QTC intervals in their subjects treated 
with fexofenadine.
In an industry-sponsored study, Meltzer et al (2004) 
studied the safety and efﬁ  cacy of fexofenadine in children 
with seasonal allergic rhinitis. They polled data from 
3 double-blind, randomized, placebo-controlled, parallel 
group, 2-week trials in children ages 6 to 11 years with 
seasonal allergic rhinitis. The studies used 30 mg twice daily 
while 2 other studies also used 15 or 60 mg twice daily. Journal of Asthma and Allergy 2008:1 25
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Adverse events did not differ between the fexofenadine and 
placebo groups. Headache was the most common adverse 
event. They did not identify any sedative effect of fexof-
enadine. Fexofenadine at 30 mg twice daily signiﬁ  cantly 
reduced the total symptom score, sneeze, rhinorrhea, itchy 
nose/mouth/throat/ears, itchy watery red eyes, and nasal con-
gestion. Kawashima et al (2002) found that doses as low as 
20 mg twice daily were effective in the treatment of chronic 
idiopathic urticaria, and in another study, Kawashima et al 
(2003) found that fexofenadine improved the pruritus associ-
ated with atopic dermatitis more than placebo.
With assistance from industry, Nelson et al (2000) tested 
the efﬁ  cacy of fexofenadine in the treatment of chronic idio-
pathic urticaria. Fexofenadine administered over a period of 
4 weeks was better than placebo. They noted no signiﬁ  cant 
differences in the responses to doses between 60 mg twice 
daily and 240 mg twice daily. All subjects noted improve-
ment in pruritus severity, number of wheals, and interference 
with sleep. Handa et al (2004) did not ﬁ  nd great beneﬁ  t of 
fexofenadine n the treatment of chronic idiopathic urticaria. 
In an open-label, non-comparative study, Kulthanan et al 
(2001) studied the efﬁ  cacy and toxicity of fexofenadine in 
the treatment of chronic idiopathic urticaria. Of 108 patients 
enrolled, 10 withdrew for lack of efﬁ  cacy. Fexofenadine 
reduced the number of wheals, the severity of itch, interfer-
ence with sleep, and interference with daily activities. Twenty 
subjects experienced at least one adverse event. The adverse 
events included headache, drowsiness, dizziness, increased 
appetite with weight gain, and cough.
With industry support, Russell et al (1998) studied the 
fexofenadine dose and subject tolerance to fexofenadine, 
as well as the drug single dose and steady-state pharmaco-
kinetics in 87 adult subjects. Their subjects tolerated doses 
of fexofenadine ranging from 10 to 800 mg, with no clini-
cally signiﬁ  cant trends for cardiac conduction parameters, 
vital signs, adverse event reporting, or clinical labora-
tory parameters despite exposure to fexofenadine plasma 
concentrations as high as 12,250 ng/mL. At doses of 15 and 
30 mg twice daily in children aged 6 months to 2 years 
with allergic rhinitis, treatment-emergent adverse events 
were similar between the placebo and treatment groups. 
Vomiting was the most common adverse event. There were 
no differences between fexofenadine and placebo for vital 
signs, electrocardiographic results, or physical examination 
results (Hampel et al 2007). An industry study of the effect 
of fexofenadine in a single dose up to 800 mg and multiple 
doses of 690 mg did not appear to change the QTc interval 
(Pratt et al 1999).
Pinto et al (et al 1999) described a patient on fexofenadine 
with a prolonged QTc interval. While on fexofenadine, 
the patient experienced an episode of syncope, with injury 
to a tooth. Taken off the fexofenadine, the patient’s QTc 
interval normalized. When replaced on fexofenadine 180 mg 
daily, QTc interval increased and the patient experienced 
an episode of polymorphic ventricular tachycardia, which 
progressed to ventricular ﬁ  brillation. The authors did not 
ﬁ  nd an alternative reason for the prolonged QTc interval or 
the ventricular arrhythmia. Industry contested this ﬁ  nding. 
However, in a response, Pinto et al addressed industry’s 
concerns. (Giraud and Giraud 1999). Craig-McFeely et al 
(2000, 2001) surveyed general practitioners in Britain for 
adverse events to fexofenadine. Less than 1% of respon-
dents stopped the fexofenadine for intolerance. They found 
no reports of drug interactions. Cardiac events, including 
palpitations, chest pain, arrhythmia, and chest tightness, but 
without reports of QTc interval lengthening, resolved upon 
cessation of the drug. Dhar et al (2000) were unable to ﬁ  nd 
QTc prolongation with fexofenadine.
Hindmarch et al with industry support, studied the effect 
of fexofenadine upon cognitive and psychomotor function 
(Hindmarch et al 1999, 2002; Kamei et al 2003; Ridout et al 
2003a, b). The authors tested critical ﬂ  icker fusion (CFF), 
choice reaction time (CRT), and assessment of subjective 
sedation (LARS) after up to 180 mg fexofenadine, from 1 to 
24 hours. They were unable to ﬁ  nd a difference between 
fexofenadine and placebo. Stone et al (1999) studied the 
central effects of fexofenadine (120, 180 and 240 mg) on 
digit symbol substitution, tracking and vigilance tasks and 
on objective sleepiness (multiple sleep latency test) and sub-
jective sleepiness. They found no effect of the fexofenadine 
on any of these variables. Potter et al (2003) were unable to 
ﬁ  nd differences in reaction time, decision-making, and driver 
behavior with and without fexofenadine 180 mg compared to 
placebo. They found no differences between the fexofenadine 
and the placebo groups. Nicholson et al (2000) found that 
fexofenadine in doses of 120 g, 180 mg, and 240 mg did not 
affect digit symbol substitution, tracking, vigilance tasks, 
multiple sleep latencies, and subjective sleepiness. Mansﬁ  eld 
et al (2003) found that fexofenadine at a dose of 180 mg 
did not change self-reported drowsiness, omission errors, 
and response time. Bower et al (2003) studied the effects of 
single-dose fexofenadine, diphenhydramine, and placebo on 
cognitive performance in ﬂ  ight personnel. Although diphen-
hydramine resulted in signiﬁ  cant psychomotor decrements, 
the effect of fexofenadine was not different from placebo. 
In an industry-supported study, Tashiro et al (2005) studied Journal of Asthma and Allergy 2008:1 26
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the effect of fexofenadine upon brake reaction time, while 
using a cellular phone. Compared to hydroxyzine, fexof-
enadine did not impair brake reaction time in otherwise 
healthy subjects. Weiler et al (2000) compared the effects 
of fexofenadine, diphenhydramine, and alcohol on driving 
performance. Subjects received one of these drugs or placebo, 
weekly, 1 hour prior to driving. Subjects had signiﬁ  cantly 
better coherence after taking alcohol or fexofenadine than 
after taking diphenhydramine. Lane keeping (steering insta-
bility and crossing the centerline) was impaired after alcohol 
and diphenhydramine use compared with fexofenadine use. 
Alcohol increased the mean response time to stop the vehicle 
compared to fexofenadine. Self-reported drowsiness did not 
predict lack of coherence and weakly related to the minimum 
following distance, steering instability, and left lane excur-
sion. In a review by Banerji et al (2007), the authors found 
that fexofenadine was less sedating than diphenhydramine.
Graft et al (2001), in an industry-sponsored study, 
demonstrated the safety of fexofenadine in 875 children, 
6 to 11 years of age, treated for seasonal allergic rhinitis. 
They administered 15 mg, 30 mg, or 60 mg, twice daily. Ten 
of their subjects (5 in the fexofenadine group and 5 in the 
placebo group) stopped the medication because of an adverse 
event, which included upper respiratory congestion, otitis 
media, and asthma, although the authors could not link any 
of the adverse events to the drug. They reported no changes 
in electrocardiograms.
Saraswat et al (2006) presented a case of stable psoriasis, 
who developed a severe pustular ﬂ  are within 24 hours of 
taking fexofenadine. Following resolution of the pustular 
psoriasis, they rechallenged the patient with fexofenadine, 
with recurrence of the rash. These studies support the conten-
tion that fexofenadine is effective for the treatment of allergic 
rhinits and chronic idiopathic urticaria, perhaps without 
beneﬁ  t to patients with asthma. With the possible exception 
of rare adverse cardiac and cutaneous events, fexofenadine 
appears no more toxic than placebo when administered in 
the absence of other drugs.
Conclusion
The FDA approved fexofenadine for treatment of the symp-
toms of allergic rhinitis and chronic idiopathic urticaria. 
The drug appeared effective in the treatment of its indicated 
conditions. Subjects tolerated fexofenadine well. However, 
concern remains regarding fexofenadine’s interactions 
with other medications that use the P-glycoprotein and the 
organic anion transporter peptides, which may result in an 
increased risk of adverse events to those other medications. 
This concern comes from the pharmacokinetic data, which 
suggest that although only a small proportion of fexofena-
dine is metabolized, fexofenadine moves into and out of the 
blood and tissues by at least P-glycoprotein and organic 
anion transporter peptides, which transport a number of other 
medications. In addition to blocking H1 receptors, fexof-
enadine appears to diminish the production of LTC4, LTD4, 
and LTE4, PGE2, and PGF2α; inhibits cyclo-oxygenase 2; 
inhibits the generation of thromboxane (perhaps through 
cyclo-oxygenase 2); and limits iNOS generation of NO, as 
well as ICAM-1, ELAM-1, VCAM-1, RANTES, I-TAC, 
MDC, TARC, MMP-2, MMP-9, and tryptase, which may 
contribute to its beneﬁ  t.
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